Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 12/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256085 | 0.91 | PTGER1 (0.51) | HCRTR2HCRTR1PTGER1PKM | |
| SCHEMBL14107539 | 0.90 | HCRTR2 (0.59) | HCRTR2HCRTR1PKM | |
| SCHEMBL14107542 | 0.82 | HCRTR2 (0.60) | HCRTR2HCRTR1PKM | |
| SCHEMBL4869109 | 0.82 | HCRTR2 (0.57) | HCRTR2HCRTR1PKM | |
| SCHEMBL5458205 | 0.81 | HCRTR2 (0.59) | HCRTR2HCRTR1PKM | |
| SCHEMBL3247753 | 0.81 | PKM (0.57) | HCRTR2HCRTR1PTGER1PKM | |
| SCHEMBL4866240 | 0.81 | HCRTR2 (0.57) | HCRTR2HCRTR1PKM | |
| SCHEMBL4867736 | 0.81 | HPGD (0.53) | HCRTR2HCRTR1PTGER1PKM | |
| SCHEMBL3250704 | 0.80 | KEAP1 (0.55) | HCRTR2HCRTR1PTGER1PKM | |
| SCHEMBL4871475 | 0.80 | HPGD (0.59) | HCRTR2HCRTR1PTGER1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| WO-2006024779-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HCRTR2, GIPR, SSTR2 | HCRTR2 1/4885HCRTR1 6/4885PTGER1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.